{"entity":{"id":"lb1410","kind":"drug","name":"LB1410","aka":[],"tldr":"LB1410 is an experimental bispecific antibody from L & L Bio, Ningbo, China in phase 2 trials, aimed at PD-1 and TIM-3.","summary":"LB1410 is a bispecific antibody developed by L & L Bio, Ningbo, China. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM3). The sponsor states: Anti-PD-1/TIM3 bispecific antibody intended to block dual immune checkpoint pathways, given in combination with LB4330. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of LB1410","url":"https://clinicaltrials.gov/search?intr=LB1410"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["pd1","tim3"],"drugs":[],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06468358"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"Anti-PD-1/TIM3 bispecific antibody intended to block dual immune checkpoint pathways, given in combination with LB4330.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lb1410/","neighbours":{"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"tim3","kind":"target","name":"TIM-3","route":"/targets/tim3/"}],"company":[{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}],"trial":[{"id":"nct06468358","kind":"trial","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct06468358/"}]}}